stoxline Quote Chart Rank Option Currency Glossary
  
Kazia Therapeutics Limited (KZIA)
0.376  0.031 (8.99%)    04-19 16:00
Open: 0.341
High: 0.407
Volume: 295,984
  
Pre. Close: 0.345
Low: 0.3351
Market Cap: 9(M)
Technical analysis
2024-04-19 5:10:38 PM
Short term     
Mid term     
Targets 6-month :  0.58 1-year :  0.68
Resists First :  0.5 Second :  0.58
Pivot price 0.35
Supports First :  0.32 Second :  0.2
MAs MA(5) :  0.33 MA(20) :  0.34
MA(100) :  0.34 MA(250) :  0.73
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  42.1 D(3) :  32.8
RSI RSI(14): 57.3
52-week High :  1.49 Low :  0.18
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ KZIA ] has closed below upper band by 39.7%. Bollinger Bands are 2.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.41 - 0.41 0.41 - 0.41
Low: 0.33 - 0.33 0.33 - 0.33
Close: 0.37 - 0.38 0.38 - 0.38
Company Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Headline News

Tue, 16 Apr 2024
Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Increase in Short Interest - Defense World

Thu, 21 Mar 2024
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases - Newswise

Wed, 13 Mar 2024
Kazia announces presentation of new data at AACR Annual Meeting – Company Announcement - Financial Times

Wed, 21 Feb 2024
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint - PR Newswire

Sun, 18 Feb 2024
Biotech Ventures: Capitalize on Innovation - DataDrivenInvestor

Thu, 18 Jan 2024
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -7 (M)
Shares Float 0 (M)
Held by Insiders 2.636e+007 (%)
Held by Institutions 2.19e+008 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.74
Profit Margin 0 %
Operating Margin -148 %
Return on Assets (ttm) 56 %
Return on Equity (ttm) 737.5 %
Qtrly Rev. Growth -186.4 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.98
Qtrly Earnings Growth -1.752e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -0.52
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 259530
Forward Dividend 765130
Dividend Yield 69023900%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android